U.S. Markets closed
  • S&P 500

    3,901.36
    +0.57 (+0.01%)
     
  • Dow 30

    31,261.90
    +8.77 (+0.03%)
     
  • Nasdaq

    11,354.62
    -33.88 (-0.30%)
     
  • Russell 2000

    1,773.27
    -2.96 (-0.17%)
     
  • Crude Oil

    110.35
    +0.46 (+0.42%)
     
  • Gold

    1,845.10
    +3.90 (+0.21%)
     
  • Silver

    21.87
    -0.03 (-0.13%)
     
  • EUR/USD

    1.0562
    -0.0026 (-0.24%)
     
  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     
  • GBP/USD

    1.2495
    +0.0020 (+0.16%)
     
  • USD/JPY

    127.8500
    +0.0560 (+0.04%)
     
  • BTC-USD

    29,987.83
    +680.96 (+2.32%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

This Breakout Healthcare Growth Stock Is Too Cheap to Miss

·4 min read
This Breakout Healthcare Growth Stock Is Too Cheap to Miss
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Before the pandemic, Fulgent Genetics (NASDAQ: FLGT) was a little-known genetic testing business with grand ambitions but limited means. Let's take a brief walk through Fulgent Genetics' business and the inexpensive valuation of its shares to see if it might be a good fit for your portfolio in 2022. The bottom line with Fulgent Genetics is that the company's early pandemic pivot into providing coronavirus testing has built strong financial and logistical foundations that it can now use to grow with abandon.